share_log

There Are Reasons To Feel Uneasy About Topchoice Medical's (SHSE:600763) Returns On Capital

There Are Reasons To Feel Uneasy About Topchoice Medical's (SHSE:600763) Returns On Capital

有理由對Topchoice Medical(SHSE: 600763)的資本回報率感到不安
Simply Wall St ·  02/26 18:30

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. However, after investigating Topchoice Medical (SHSE:600763), we don't think it's current trends fit the mold of a multi-bagger.

我們應該尋找哪些趨勢?我們想確定可以長期價值成倍增長的股票?理想情況下,企業將表現出兩種趨勢;首先是增長 返回 論資本使用率(ROCE),其次是增加 金額 所用資本的比例。這向我們表明,它是一臺複合機器,能夠持續將其收益再投資到業務中併產生更高的回報。但是,在調查了Topchoice Medical(SHSE: 600763)之後,我們認爲目前的趨勢不符合多袋機的模式。

What Is Return On Capital Employed (ROCE)?

什麼是資本使用回報率(ROCE)?

If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. The formula for this calculation on Topchoice Medical is:

如果你以前沒有與ROCE合作過,它會衡量公司從其業務中使用的資本中產生的 “回報”(稅前利潤)。在 Topchoice Medical 上進行此計算的公式爲:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

已動用資本回報率 = 息稅前收益 (EBIT) ¥(總資產-流動負債)

0.14 = CN¥738m ÷ (CN¥5.8b - CN¥437m) (Based on the trailing twelve months to September 2023).

0.14 = CN¥738m ≤(CN¥5.8b-CN¥4.37m) (基於截至2023年9月的過去十二個月)

So, Topchoice Medical has an ROCE of 14%. In absolute terms, that's a satisfactory return, but compared to the Healthcare industry average of 11% it's much better.

因此,Topchoice Medical的投資回報率爲14%。從絕對值來看,這是一個令人滿意的回報,但與醫療保健行業的平均水平11%相比,回報要好得多。

roce
SHSE:600763 Return on Capital Employed February 26th 2024
SHSE: 600763 2024 年 2 月 26 日動用資本回報率

Above you can see how the current ROCE for Topchoice Medical compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Topchoice Medical .

上面你可以看到Topchoice Medical當前的投資回報率與其先前的資本回報率相比如何,但從過去可以看出來的只有那麼多。如果你想了解分析師對未來的預測,你應該查看我們的Topchoice Medical免費分析師報告。

The Trend Of ROCE

ROCE 的趨勢

When we looked at the ROCE trend at Topchoice Medical, we didn't gain much confidence. To be more specific, ROCE has fallen from 22% over the last five years. On the other hand, the company has been employing more capital without a corresponding improvement in sales in the last year, which could suggest these investments are longer term plays. It may take some time before the company starts to see any change in earnings from these investments.

當我們研究Topchoice Medical的投資回報率趨勢時,我們並沒有獲得太大的信心。更具體地說,投資回報率已從過去五年的22%下降。另一方面,該公司在去年一直在使用更多資本,但銷售額沒有相應改善,這可能表明這些投資是長期投資。公司可能需要一段時間才能開始看到這些投資的收益發生任何變化。

In Conclusion...

總之...

In summary, Topchoice Medical is reinvesting funds back into the business for growth but unfortunately it looks like sales haven't increased much just yet. And with the stock having returned a mere 10% in the last five years to shareholders, you could argue that they're aware of these lackluster trends. As a result, if you're hunting for a multi-bagger, we think you'd have more luck elsewhere.

總而言之,Topchoice Medical正在將資金再投資回該業務以實現增長,但不幸的是,銷售額似乎還沒有太大增長。而且,由於該股在過去五年中僅向股東回報了10%,因此你可以說他們意識到了這些乏善可陳的趨勢。因此,如果你正在尋找一臺多袋裝機,我們認爲你在其他地方會有更多的運氣。

Topchoice Medical could be trading at an attractive price in other respects, so you might find our free intrinsic value estimation for 600763 on our platform quite valuable.

Topchoice Medical在其他方面可能以誘人的價格進行交易,因此您可能會發現我們在我們的平台上對600763的免費內在價值估算非常有價值。

If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.

如果你想尋找收益豐厚的穩健公司,可以免費查看這份資產負債表良好且股本回報率可觀的公司名單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論